Mr. Timothy Ko reports

ENTHEON BIOMEDICAL ANNOUNCES PRIVATE PLACEMENT FINANCING UPSIZE TO $500,000

Entheon Biomedical Corp. has increased its private placement financing to up to five million units at a price of 10 cents per unit for gross proceeds of up to $500,000 referenced to the news release dated Dec. 2, 2024.

Each unit will consist of one common share in the capital of the company and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share at an exercise price of 15 cents per share for a period of 24 months from the date of issuance.

The sale of the shares and warrant shares will result in the issuance of more than 100 per cent of the number of issued and outstanding shares of the company immediately prior to the closing of the offering. The Canadian Securities Exchange approved the company's reliance on an exemption from the shareholder approval requirements in Section 4.6(2)(b) of CSE Policy 4, Corporate Governance, Security Holder Approvals and Miscellaneous Provisions, on the basis that the company was in serious financial difficulty and that the company's independent directors determined that the offering was in the best interests of the company and that it was not feasible to obtain securityholder approval in a timely manner. No related persons (as that term is defined in the policies of the CSE) participated in the offering. Accordingly, the company did not hold a vote of its shareholders to approve the sale of the units under the offering.

The company intends to use the proceeds from the placement toward general working capital purposes. All securities issued under the placement will be subject to a four-month-and-one-day hold period and the company may pay finders' fees in accordance with the policies of the CSE.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

We seek Safe Harbor.